Isothiocyanates inhibit psoriasis-related proinflammatory factors in human skin
Objective 4-Methylthiobutylisothiocyanate (MTBI), the main rocket ( Eruca sativa ) seed isothiocyanate (ITC), and its oxidized form, sulforaphane (SFN), were assessed for their potential effects on psoriasis-related factors. Methods MTBI and SFN were evaluated for their effect on mRNA expression and...
Gespeichert in:
| Veröffentlicht in: | Inflammation research 2012-07, Vol.61 (7), p.735-742 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 742 |
|---|---|
| container_issue | 7 |
| container_start_page | 735 |
| container_title | Inflammation research |
| container_volume | 61 |
| creator | Yehuda, Hila Soroka, Yoram Zlotkin-Frušić, Marina Gilhar, Amos Milner, Yoram Tamir, Snait |
| description | Objective
4-Methylthiobutylisothiocyanate (MTBI), the main rocket (
Eruca sativa
) seed isothiocyanate (ITC), and its oxidized form, sulforaphane (SFN), were assessed for their potential effects on psoriasis-related factors.
Methods
MTBI and SFN were evaluated for their effect on mRNA expression and cytokine secretion in vitro in human monocytes and macrophage-like cells and ex vivo in topically treated inflamed human skin. In addition, they were assayed in vivo for morphological changes in topically treated psoriasiform human skin in severe-combined immunodeficient (SCID) mice.
Results
MTBI and SFN contributed to the prevention of inflammation development and reduced ongoing inflammation by downregulating lipopolysaccharide (LPS)-induced mRNA expression of the psoriasis-related cytokines, interleukin (IL)-12/23p40 (25–58 %), tumor necrosis factor (TNF)-α (15–37 %) and IL-6 (25–71 %), in human macrophage-like cells. In monocytes, they tended to act additively on cytokine mRNA and reduced IL-12/23p40 (51 %) secretion. In an ex-vivo inflamed human skin organ culture, MTBI (1 μg/ml) reduced the secretion of IL-1 (39 %) and IL-6 (32 %). Moreover, 2/8 and 3/8 of the MTBI- and SFN-treated psoriasiform SCID mice, respectively, recovered partially or entirely from the psoriasiform process.
Conclusions
Results from these models indicate the potential of rocket seed ITCs as biological agents in the therapy of psoriasis and inflammation-related skin diseases. |
| doi_str_mv | 10.1007/s00011-012-0465-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1468381029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1020833235</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-e1204d0eb19f85fda56155e41eca42ae0c576d8286f8f9c66441827b585eb5f53</originalsourceid><addsrcrecordid>eNqFkUtLxDAUhYMozjj6A9xIwY2b6M2rTZcy-BgYmI2Cu5K2iZOxjzFpF_PvTe0oIoire-F-59ybHITOCVwTgOTGAwAhGAjFwGOB2QGaEk4BpyBfDkMPlGEmGUzQifebQEsq6TGaUMoFk5xO0Wrh225t22KnGtVpH9lmbXPbRVvfOqu89djpKkzKaOta25hK1bXqWreLjCpCHRTRuq9VE_k325yiI6Mqr8_2dYae7--e5o94uXpYzG-XuOAJ6bAmFHgJOiepkcKUSsRECM2JLhSnSkMhkrgM18ZGmrSIY86JpEkupNC5MILN0NXoG65677Xvstr6QleVanTb-4zwWDIZPiD9HwUKkjHKBtfLX-im7V0THvJJkUSCGAzJSBWu9d5pk22drZXbBSgbgsnGYLIQTDYEk7Ggudg793mty2_FVxIBoCPgw6h51e7n6r9cPwCrt5fQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1020178059</pqid></control><display><type>article</type><title>Isothiocyanates inhibit psoriasis-related proinflammatory factors in human skin</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Yehuda, Hila ; Soroka, Yoram ; Zlotkin-Frušić, Marina ; Gilhar, Amos ; Milner, Yoram ; Tamir, Snait</creator><creatorcontrib>Yehuda, Hila ; Soroka, Yoram ; Zlotkin-Frušić, Marina ; Gilhar, Amos ; Milner, Yoram ; Tamir, Snait</creatorcontrib><description>Objective
4-Methylthiobutylisothiocyanate (MTBI), the main rocket (
Eruca sativa
) seed isothiocyanate (ITC), and its oxidized form, sulforaphane (SFN), were assessed for their potential effects on psoriasis-related factors.
Methods
MTBI and SFN were evaluated for their effect on mRNA expression and cytokine secretion in vitro in human monocytes and macrophage-like cells and ex vivo in topically treated inflamed human skin. In addition, they were assayed in vivo for morphological changes in topically treated psoriasiform human skin in severe-combined immunodeficient (SCID) mice.
Results
MTBI and SFN contributed to the prevention of inflammation development and reduced ongoing inflammation by downregulating lipopolysaccharide (LPS)-induced mRNA expression of the psoriasis-related cytokines, interleukin (IL)-12/23p40 (25–58 %), tumor necrosis factor (TNF)-α (15–37 %) and IL-6 (25–71 %), in human macrophage-like cells. In monocytes, they tended to act additively on cytokine mRNA and reduced IL-12/23p40 (51 %) secretion. In an ex-vivo inflamed human skin organ culture, MTBI (1 μg/ml) reduced the secretion of IL-1 (39 %) and IL-6 (32 %). Moreover, 2/8 and 3/8 of the MTBI- and SFN-treated psoriasiform SCID mice, respectively, recovered partially or entirely from the psoriasiform process.
Conclusions
Results from these models indicate the potential of rocket seed ITCs as biological agents in the therapy of psoriasis and inflammation-related skin diseases.</description><identifier>ISSN: 1023-3830</identifier><identifier>EISSN: 1420-908X</identifier><identifier>DOI: 10.1007/s00011-012-0465-3</identifier><identifier>PMID: 22453842</identifier><language>eng</language><publisher>Basel: SP Birkhäuser Verlag Basel</publisher><subject>Adolescent ; Adult ; Allergology ; Animals ; Biomedical and Life Sciences ; Biomedicine ; Cell Line ; Cytokines - genetics ; Cytokines - metabolism ; Dermatology ; Eruca sativa ; Female ; Humans ; Immunology ; Intercellular Adhesion Molecule-1 - genetics ; Isothiocyanates - pharmacology ; Isothiocyanates - therapeutic use ; Mice ; Mice, SCID ; Middle Aged ; Monocytes - cytology ; Monocytes - drug effects ; Neurology ; Original Research Paper ; Pharmacology/Toxicology ; Psoriasis - drug therapy ; Psoriasis - metabolism ; Rheumatology ; RNA, Messenger - metabolism ; Skin - drug effects ; Thiocyanates - pharmacology ; Thiocyanates - therapeutic use ; Transplantation, Heterologous ; Young Adult</subject><ispartof>Inflammation research, 2012-07, Vol.61 (7), p.735-742</ispartof><rights>Springer Basel AG 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-e1204d0eb19f85fda56155e41eca42ae0c576d8286f8f9c66441827b585eb5f53</citedby><cites>FETCH-LOGICAL-c471t-e1204d0eb19f85fda56155e41eca42ae0c576d8286f8f9c66441827b585eb5f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00011-012-0465-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00011-012-0465-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22453842$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yehuda, Hila</creatorcontrib><creatorcontrib>Soroka, Yoram</creatorcontrib><creatorcontrib>Zlotkin-Frušić, Marina</creatorcontrib><creatorcontrib>Gilhar, Amos</creatorcontrib><creatorcontrib>Milner, Yoram</creatorcontrib><creatorcontrib>Tamir, Snait</creatorcontrib><title>Isothiocyanates inhibit psoriasis-related proinflammatory factors in human skin</title><title>Inflammation research</title><addtitle>Inflamm. Res</addtitle><addtitle>Inflamm Res</addtitle><description>Objective
4-Methylthiobutylisothiocyanate (MTBI), the main rocket (
Eruca sativa
) seed isothiocyanate (ITC), and its oxidized form, sulforaphane (SFN), were assessed for their potential effects on psoriasis-related factors.
Methods
MTBI and SFN were evaluated for their effect on mRNA expression and cytokine secretion in vitro in human monocytes and macrophage-like cells and ex vivo in topically treated inflamed human skin. In addition, they were assayed in vivo for morphological changes in topically treated psoriasiform human skin in severe-combined immunodeficient (SCID) mice.
Results
MTBI and SFN contributed to the prevention of inflammation development and reduced ongoing inflammation by downregulating lipopolysaccharide (LPS)-induced mRNA expression of the psoriasis-related cytokines, interleukin (IL)-12/23p40 (25–58 %), tumor necrosis factor (TNF)-α (15–37 %) and IL-6 (25–71 %), in human macrophage-like cells. In monocytes, they tended to act additively on cytokine mRNA and reduced IL-12/23p40 (51 %) secretion. In an ex-vivo inflamed human skin organ culture, MTBI (1 μg/ml) reduced the secretion of IL-1 (39 %) and IL-6 (32 %). Moreover, 2/8 and 3/8 of the MTBI- and SFN-treated psoriasiform SCID mice, respectively, recovered partially or entirely from the psoriasiform process.
Conclusions
Results from these models indicate the potential of rocket seed ITCs as biological agents in the therapy of psoriasis and inflammation-related skin diseases.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Allergology</subject><subject>Animals</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cell Line</subject><subject>Cytokines - genetics</subject><subject>Cytokines - metabolism</subject><subject>Dermatology</subject><subject>Eruca sativa</subject><subject>Female</subject><subject>Humans</subject><subject>Immunology</subject><subject>Intercellular Adhesion Molecule-1 - genetics</subject><subject>Isothiocyanates - pharmacology</subject><subject>Isothiocyanates - therapeutic use</subject><subject>Mice</subject><subject>Mice, SCID</subject><subject>Middle Aged</subject><subject>Monocytes - cytology</subject><subject>Monocytes - drug effects</subject><subject>Neurology</subject><subject>Original Research Paper</subject><subject>Pharmacology/Toxicology</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis - metabolism</subject><subject>Rheumatology</subject><subject>RNA, Messenger - metabolism</subject><subject>Skin - drug effects</subject><subject>Thiocyanates - pharmacology</subject><subject>Thiocyanates - therapeutic use</subject><subject>Transplantation, Heterologous</subject><subject>Young Adult</subject><issn>1023-3830</issn><issn>1420-908X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkUtLxDAUhYMozjj6A9xIwY2b6M2rTZcy-BgYmI2Cu5K2iZOxjzFpF_PvTe0oIoire-F-59ybHITOCVwTgOTGAwAhGAjFwGOB2QGaEk4BpyBfDkMPlGEmGUzQifebQEsq6TGaUMoFk5xO0Wrh225t22KnGtVpH9lmbXPbRVvfOqu89djpKkzKaOta25hK1bXqWreLjCpCHRTRuq9VE_k325yiI6Mqr8_2dYae7--e5o94uXpYzG-XuOAJ6bAmFHgJOiepkcKUSsRECM2JLhSnSkMhkrgM18ZGmrSIY86JpEkupNC5MILN0NXoG65677Xvstr6QleVanTb-4zwWDIZPiD9HwUKkjHKBtfLX-im7V0THvJJkUSCGAzJSBWu9d5pk22drZXbBSgbgsnGYLIQTDYEk7Ggudg793mty2_FVxIBoCPgw6h51e7n6r9cPwCrt5fQ</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Yehuda, Hila</creator><creator>Soroka, Yoram</creator><creator>Zlotkin-Frušić, Marina</creator><creator>Gilhar, Amos</creator><creator>Milner, Yoram</creator><creator>Tamir, Snait</creator><general>SP Birkhäuser Verlag Basel</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120701</creationdate><title>Isothiocyanates inhibit psoriasis-related proinflammatory factors in human skin</title><author>Yehuda, Hila ; Soroka, Yoram ; Zlotkin-Frušić, Marina ; Gilhar, Amos ; Milner, Yoram ; Tamir, Snait</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-e1204d0eb19f85fda56155e41eca42ae0c576d8286f8f9c66441827b585eb5f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Allergology</topic><topic>Animals</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cell Line</topic><topic>Cytokines - genetics</topic><topic>Cytokines - metabolism</topic><topic>Dermatology</topic><topic>Eruca sativa</topic><topic>Female</topic><topic>Humans</topic><topic>Immunology</topic><topic>Intercellular Adhesion Molecule-1 - genetics</topic><topic>Isothiocyanates - pharmacology</topic><topic>Isothiocyanates - therapeutic use</topic><topic>Mice</topic><topic>Mice, SCID</topic><topic>Middle Aged</topic><topic>Monocytes - cytology</topic><topic>Monocytes - drug effects</topic><topic>Neurology</topic><topic>Original Research Paper</topic><topic>Pharmacology/Toxicology</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis - metabolism</topic><topic>Rheumatology</topic><topic>RNA, Messenger - metabolism</topic><topic>Skin - drug effects</topic><topic>Thiocyanates - pharmacology</topic><topic>Thiocyanates - therapeutic use</topic><topic>Transplantation, Heterologous</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yehuda, Hila</creatorcontrib><creatorcontrib>Soroka, Yoram</creatorcontrib><creatorcontrib>Zlotkin-Frušić, Marina</creatorcontrib><creatorcontrib>Gilhar, Amos</creatorcontrib><creatorcontrib>Milner, Yoram</creatorcontrib><creatorcontrib>Tamir, Snait</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Inflammation research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yehuda, Hila</au><au>Soroka, Yoram</au><au>Zlotkin-Frušić, Marina</au><au>Gilhar, Amos</au><au>Milner, Yoram</au><au>Tamir, Snait</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Isothiocyanates inhibit psoriasis-related proinflammatory factors in human skin</atitle><jtitle>Inflammation research</jtitle><stitle>Inflamm. Res</stitle><addtitle>Inflamm Res</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>61</volume><issue>7</issue><spage>735</spage><epage>742</epage><pages>735-742</pages><issn>1023-3830</issn><eissn>1420-908X</eissn><abstract>Objective
4-Methylthiobutylisothiocyanate (MTBI), the main rocket (
Eruca sativa
) seed isothiocyanate (ITC), and its oxidized form, sulforaphane (SFN), were assessed for their potential effects on psoriasis-related factors.
Methods
MTBI and SFN were evaluated for their effect on mRNA expression and cytokine secretion in vitro in human monocytes and macrophage-like cells and ex vivo in topically treated inflamed human skin. In addition, they were assayed in vivo for morphological changes in topically treated psoriasiform human skin in severe-combined immunodeficient (SCID) mice.
Results
MTBI and SFN contributed to the prevention of inflammation development and reduced ongoing inflammation by downregulating lipopolysaccharide (LPS)-induced mRNA expression of the psoriasis-related cytokines, interleukin (IL)-12/23p40 (25–58 %), tumor necrosis factor (TNF)-α (15–37 %) and IL-6 (25–71 %), in human macrophage-like cells. In monocytes, they tended to act additively on cytokine mRNA and reduced IL-12/23p40 (51 %) secretion. In an ex-vivo inflamed human skin organ culture, MTBI (1 μg/ml) reduced the secretion of IL-1 (39 %) and IL-6 (32 %). Moreover, 2/8 and 3/8 of the MTBI- and SFN-treated psoriasiform SCID mice, respectively, recovered partially or entirely from the psoriasiform process.
Conclusions
Results from these models indicate the potential of rocket seed ITCs as biological agents in the therapy of psoriasis and inflammation-related skin diseases.</abstract><cop>Basel</cop><pub>SP Birkhäuser Verlag Basel</pub><pmid>22453842</pmid><doi>10.1007/s00011-012-0465-3</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1023-3830 |
| ispartof | Inflammation research, 2012-07, Vol.61 (7), p.735-742 |
| issn | 1023-3830 1420-908X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1468381029 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adolescent Adult Allergology Animals Biomedical and Life Sciences Biomedicine Cell Line Cytokines - genetics Cytokines - metabolism Dermatology Eruca sativa Female Humans Immunology Intercellular Adhesion Molecule-1 - genetics Isothiocyanates - pharmacology Isothiocyanates - therapeutic use Mice Mice, SCID Middle Aged Monocytes - cytology Monocytes - drug effects Neurology Original Research Paper Pharmacology/Toxicology Psoriasis - drug therapy Psoriasis - metabolism Rheumatology RNA, Messenger - metabolism Skin - drug effects Thiocyanates - pharmacology Thiocyanates - therapeutic use Transplantation, Heterologous Young Adult |
| title | Isothiocyanates inhibit psoriasis-related proinflammatory factors in human skin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T06%3A07%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Isothiocyanates%20inhibit%20psoriasis-related%20proinflammatory%20factors%20in%20human%20skin&rft.jtitle=Inflammation%20research&rft.au=Yehuda,%20Hila&rft.date=2012-07-01&rft.volume=61&rft.issue=7&rft.spage=735&rft.epage=742&rft.pages=735-742&rft.issn=1023-3830&rft.eissn=1420-908X&rft_id=info:doi/10.1007/s00011-012-0465-3&rft_dat=%3Cproquest_cross%3E1020833235%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1020178059&rft_id=info:pmid/22453842&rfr_iscdi=true |